Prion diseases - Close to effective therapy?

Nature Reviews Drug Discovery

Volumn 3, Issue 10, 2004, Pages 874-884

  Cashman, Neil R ^a   Caughey, Byron ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; AMPHOTERICIN B; AMYLOID PRECURSOR PROTEIN; ANTIMONIOTUNGSTATE; CHLORPROMAZINE; CONGO RED; DYE; FILIPIN; GLYCAN DERIVATIVE; HEPARAN SULFATE; ISOPROTEIN; MEPACRINE; METAL DERIVATIVE; MS 8209; NEUROTOXIN; PENICILLAMINE; PENTOSAN POLYSULFATE; PHTHALOCYANINE DERIVATIVE; POLYENE ANTIBIOTIC AGENT; PORPHYRIN DERIVATIVE; PRION PROTEIN; PROTEIN ANTIBODY; PROTEIN INHIBITOR; PYRROLE DERIVATIVE; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SURAMIN; THIAZINE DERIVATIVE; UNINDEXED DRUG; VACCINE;

ANTIBODY SPECIFICITY; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CRYSTALLIZATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG PENETRATION; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HYPOTHESIS; IMMUNOLOGY; MICROORGANISM; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; TREATMENT PLANNING;

ANIMALS; CATTLE; HUMANS; IMMUNOTHERAPY, ACTIVE; PRION DISEASES;

EID: 6444225674     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1525     Document Type: Review

References (162)

1. Will, R. G. et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-925 (1996).
2. Coulthart, M. B. & Cashman, N. R. Variant Creutzfeldt-Jakob disease: a summary of current scientific knowledge in relation to public health. CMAJ 165, 51-58 (2001).
3. Ghani, A. C., Donnelly, C. A., Ferguson, N. M. & Anderson, R. M. Updated projections of future vCJD deaths in the UK. BMC Infect. Dis. 3, 4 (2003).
4. Llewelyn, C. A. et al. G. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363, 417-421 (2004).
5. Collins, S. J. et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. 52, 503-506 (2002).
6. Wadsworth, J. D. et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358, 171-180 (2001).
7. Bruce, M. E. et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389, 498-501 (1997).
8. Hill, A. F. et al. The same prion strain causes vCJD and BSE. Nature 389, 448-450 (1997).
9. Department of Environment, Food and Rural Affairs: BSE webpage [online], (2004).
10. Donnelly, C. A., Ferguson, N. M., Ghani, A. C. & Anderson, R. M. Implications of BSE infection screening data for the scale of the British BSE epidemic and current European infection levels. Proc. R. Soc. Lond. B Biol. Sci. 269, 2179-2190 (2002).
11. Schreuder, B. E. & Somerville, R. A. Bovine spongiform encelphalopathy in sheep? Rev. Sci. Tech. 22, 103-120 (2003).
12. Baylis, M. et al. BSE - a wolf in sheep's clothing. Trends Microbiol. 10, 563-570 (2002).
13. Houston, F. et al. Prion diseases: BSE in sheep bred for resistance to infection. Nature 423, 498 (2003).
14. Williams, E. S. & Young, S. Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J. Wildl. Dis. 16, 89-98 (1980).
15. Brown, P. & Bradley, R. 1755 and all that: a historical primer of transmissible spongiform encephalopathy. BMJ 317, 1688-1692 (1998).
16. Belay, E. D. et al. Chronic wasting disease and potential transmission to humans. Emerging Infect. Dis. 10, (2004).
17. Riesner, D. et al. Prions and nucleic acids: search for 'residual' nucleic acids and screening for mutations in the PrP-gene. Dev. Biol. Stand. 80, 173-181 (1993).
18. Griffith, J. S. Self-replication and scrapie. Nature 215, 1043-1044 (1967).
19. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
20. Prusiner, S. B. Prions. Proc. Natl Acad. Sci. USA 95 13363-13383 (1998).
21. Brown, P., Goldfarb, L. G. & Gajdusek, D. C. The new biology of spongiform encephalopathy: infectious amyloidoses with a genetic twist. Lancet 337, 1019-1022 (1991).
22. Caughey, B. W. et al. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30, 7672-7680 (1991).
23. Safar, J., Roller, P. P., Gajdusek, D. C. & Gibbs, C. J. Jr. Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268, 20276-20284 (1993).
24. Pan, K.-M. et al. Conversion of α-helices into β-sheets features in the formation of the scrapie prion protein. Proc. Natl Acad. Sci. USA 90, 10962-10966 (1993).
25. Riek, R., Hornemann, S., Wider, G., Glockshuber, R. & Wuthrich, K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-21). FEBS Lett. 413, 282-288 (1997).
26. Oesch, B. et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40, 735-746 (1985).
27. Meyer, R. K. et al. Separation and properties of cellular and scrapie prion protein. Proc. Natl Acad. Sci. USA 83 2310-2314 (1986).
28. Caughey, B., Race, R. E. & Chesebro, B. Detection of prion protein mRNA in normal and scrapie-infected tissues and cell lines. J. Gen. Virol. 69, 711-716 (1988).
29. Bendheim, P. E. et al. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 42, 149-156 (1992).
30. Prusiner, S. B. Molecular biology of prion diseases. Science 252, 1515-1522 (1991).
31. Come, J. H., Fraser, P. E. & Lansbury, P. T. Jr. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc. Natl Acad. Sci. USA 90, 5959-5963 (1993).
32. Kocisko, D. A. et al. Cell-free formation of brotease-resistant prion protein. Nature 370, 471-474 (1994).
33. Bessen, R. A. et al. Nongenetic, propagation of strain-specific phenotypes of scrapie prion protein. Nature 375 698-700 (1995).
34. Caughey, B. et al. Interactions and conversions of prion protein isoforms. Adv. Protein Chem. 57, 139-169 (2001).
35. Saborio, G. P., Permanne, B. & Soto, C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411, 810-813 (2001).
36. Hill, A. F., Antoniou, M. & Collinge, J. Protease-resistant prion protein produced in vitro lacks detectable infectivity. J. Gen. Virol. 80, 11-14 (1999).
37. Bessen, R. A. & Marsh, R. F. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68, 7859-7868 (1994).
38. Lasmezas, C. I. et al. Transmission of the ESE agent to mice in the absence of detectable abnormal prion protein. Science 275, 402-405 (1997).
39. Manson, J. C. et al. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 18, 6855-6864 (1999).
40. Caughey, B., Kocisko, D. A., Raymond, G. J. & Lansbury, P. T. Aggregates of scrapie associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem. Biol. 2, 807-817 (1995).
41. Kocisko, D. A., Lansbury, P. T. Jr. & Caughey, B. Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry 35, 13434-13442 (1996).
42. Safar, J. et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nature Med. 4, 1157-1165 (1998).
43. Caughey, B., Raymond, G. J., Kocisko, D. A. & Lansbury, P. T., Jr. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J. Virol. 71, 4107-4110 (1997).
44. Chiesa, R. et al. Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. Proc. Natl Acad. Sci. USA 97, 5574-5579 (2000).
45. Sc conformers induced by a synthetic peptide and several prion strains. J. Virol, 78 2088-2099 (2004).
46. Legname, G. et al. Synthetic mammalian prions. Science 305, 673-676 (2004).
47. Bueler, H. et al. Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-1347 (1993).
48. Caughey, B., Ernst, D. & Race, R. E. Congo red inhibition of scrapie agent replication. J. Virol. 67, 6270-6272 (1993).
49. Bons, N. et al. Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents. Proc. Natl Acad. Sci. USA 96, 4046-4051 (1999).
50. Sigurdson, C. J., Spraker, T. R., Miller, M. W., Oesch, B. & Hoover, E. A. PrP(CWD) in the myenteric, plexus, vagosympathetic trunk and endocrine glands of deer with chronic wasting disease. J. Gen. Virol. 82, 2327-2334 (2001).
51. Beekes, M. & McBride, P. A. Early accumulation of pathological PrP in the enteric nervous system and gut-associated lymphoid tissue of hamsters orally infected with scrapie. Neurosci. Lett. 278, 181-184 (2000).
52. Mabbott, N. A. & Bruce, M. E. The immunobiology of TSE diseases. J. Gen. Virol. 82, 2307-2318 (2001).
53. Kimberlin, R. H. & Walker, C. A. The role of the spleen in the neuroinvasion of scrapie in mice. Virus Res. 12, 201-212 (1989).
54. Bruce, M. E., McConnell, I., Will, R. G. & Ironside, J. W. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 358, 208-209 (2001).
55. Bruce, M. E., Brown, K. L., Mabbott, N. A., Farquhar, C. F. & Jeffrey, M. Follicular dendritic cells in TSE pathogenesis. Immunol. Today 21, 442-446 (2000).
56. Montracio F. et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 288, 1257-1259 (2000).
57. Klein, M. A. et al. A crucial role for B cells in neuroinvasive scrapie. Nature 390, 687-690 (1997).
58. Mabbott, N. A. et al. Tumor necrosis factor α-deficient, but not interleukin-6-deficient, mice resist peripheral infection with scrapie. J. Virol. 74, 3338-3344 (2000).
59. Brown, K. L. et al. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nature Med. 5, 1308-1312 (1999).
60. Matsumoto, M. et al. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 271 1289-1291 (1996).
61. Mabbott, N. A., Bruce, M. E., Botto, M., Walport, M. J. & Pepys, M. B. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nature Med. 7, 485-487 (2001).
62. McBride, P. A., Eikelenboom, P., Kraal, G., Fraser, H. & Bruce, M. E. PrP protein is associated with follicular dendritic cells of spleens and lymph nodes in uninfected and scrapie-infected mice. J. Pathol. 168, 413-418 (1992).
63. Heikenwalder, M., Prinz, M., Heppner, F. L. & Aguzzi, A. Current concepts and controversies in prion immunopathology. J. Mol. Neurosci. 23, 3-12 (2004).
64. Brown, D. R., Schmidt B. & Kretzschmar, H. A. Role of microglia and host prion protein in neural of a prion protein fragment. Nature 380, 345-347 (1996).
65. Klein, M. A. et al. Complement facilitates eary prion pathogenesis. Nature Med. 7, 488-492 (2001).
66. Gadjusek, D. C. in Field's Virology 3rd edn (eds Fields, B. N., Knipe, D. M. & Howley, P. M.) 2851-2900 (Lippincott-Raven, Philadelphia, 1996).
67. Enari, M., Flechsig, E. & Weissmann, C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl Acad. Sci. USA 98, 9295-9299 (2001).
68. Peretz, D. et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743 (2001)
69. Perrier, V., et al. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. J. Neurochem. 89, 454-463 (2004).
70. Heppner, F. L. et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178-182 (2001).
71. White, A. R. et al. Monoclonal antibodies inhibit prion replication and delay the development of prior disease. Nature 422, 80-83 (2003).
72. Solforosi, L. et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303, 1514-1516 (2004).
73. Mouillet-Richard, S. et al. Signal transduction through prion protein. Science 289, 1925-1928 (2000).
74. Cashman, N. R. et al. Cellular isoform at the scrapie agent protein participates in lymphocyte activation. Cell 61, 185-192 (1990).
75. Horiuchi, M., Chabry, J. & Caughey, B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J. 18, 3193-3203 (1999).
76. Caughey, B. & Raymond, G. J. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J. Biol. Chem. 266, 18217-18223 (1991).
77. Caughey, B., Raymond, G. J., Ernst, D. & Race, R. E. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. 65, 6597-6603 (1991).
78. Borchelt, D. R., Taraboulos, A. & Prusiner, S. B. Evidence for synthesis of scrapie prion protein in the endocytic pathway. J. Biol. Chem. 267, 16188-16199 (1992).
79. Taraboulos, A., Raeber, A. J., Borchelt, D. R., Serban, D. & Prusiner, S. B. Synthesis and trafficking of prion proteins in cultured cells. Mol. Biol. Cell. 3, 851-863 (1992).
80. Paramithiotis, E. et al. A prion protein epitope selective for the pathologically misfolded conformation. Nature Med. 9, 893-899 (2003).
81. Lehto, M. T., Ashman, D. A. & Cashman, N. R. Treatment of ScN2a cells with prion-specific YYR antibodies. Proc. First Intl Conf. Network Excellence: Neuroprion (Paris, 2004).
82. Schenk, D., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
83. Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54 (2003).
84. Mallucci, G. et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302 871-874 (2003).
85. C, in cultured cells. J. Biol. Chem. 270, 30221-30229 (1995).
86. Taraboulos, A. et al. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell. Biol. 129, 121-132 (1995).
87. Race, R. E., Fadness, L. H. & Chesebro, B. Characterization of scrapie infection in mouse neuroblastoma cells. J. Gen. Virol. 68, 1391-1399 (1987).
88. Butler, D. A. et al. Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J. Virol. 62, 1558-1564 (1988).
89. Clarke, M. C. & Haig, D. A. Evidence for the multiplication of scrapie agent in cell culture. Nature 225, 100-101 (1970).
90. Schatzl, H. M. et al. A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J. Virol. 71, 8821-8831 (1997).
91. Vorberg, I., Raines, A., Story, B. & Priola, S. A. Susceptibility of common fibroblast cell lines to transmissible spongiform encephalopathy agents. J. Infect Dis. 189, 431-439 (2004).
92. Sabuncu, E. et al. PrP polymorphisms tightly control sheep prion replication in cultured cells. J. Virol. 77, 2696-2700 (2003).
93. Rudyk, H. et al. Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J. Gen. Virol. 81, 1155-1164 (2000).
94. Kocisko, D. A. et al. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol. 77, 10288-10294 (2003).
95. Supattapone, S. et al. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75, 3453-3461 (2001).
96. Birkett, C. R. et al. Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. EMBO J. 20, 3351-3358 (2001).
97. Maxson, L., Wong, C., Herrmann, L. M., Caughey, B. & Baron, G. S. A solid-phase assay for identification of modulators of prion protein interactions. Anal. Biochem. 323, 54-64 (2003).
98. Horiuchi, M., Baron, G. S., Xiong, L. W. & Caughey, B. Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J. Biol. Chem. 276, 15489-15497 (2001).
99. Rhie, A. et al. Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J. Biol. Chem. 278, 39697-39705 (2003).
100. Caughey, W. S., Raymond, L. D., Horiuchi, M. & Caughey, B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl Acad. Sci. USA 95, 12117-12122 (1998).
101. Tagliavini, F., Forloni, G., D'ursi, P., Bugiani, M. & Salmona, M. Studies on peptide fragments of prion protein. Adv. Protein Chem. 57, 171-202 (2001).
102. C to a PrPSc-like form. J. Biol. Chem. 277, 43942-43947 (2002).
103. Supattapone, S. Prion protein conversion in vitro. J. Mol. Med. (2004).
104. Soto, C. et al. Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 355, 192-197 (2000).
105. Tagliavini, F. et al. Effectiveness of anthracycline against experimental prion disease in syrian hamsters. Science 276, 1119-1122 (1998).
106. Forloni, G. et al. Tetracyclines affect prion infectivity. Proc. Natl Acad. Sci. USA 99, 10849-10854 (2002).
107. SC accumulation and disease symptoms in prion-infected hamsters. Brain Res. 983, 137-143 (2003).
108. Ehlers, B. & Diringer, H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol. 65, 1325-1330 (1984).
109. Kimberlin, R. H. & Walker, C. A. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob. Agents Chemother. 30, 409-413 (1986).
110. Farquhar, C. F. & Dickinson, A. G. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J. Gen. Virol. 67, 463-473 (1986).
111. Priola, S. A., Raines, A. & Caughey, W. S. Porphyrin and phthalocyanine anti-scrapie compounds. Science 287, 1503-1506 (2000).
112. Murakami-Kubo, I. et al. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J. Virol. 78, 1281-1288 (2004).
113. Barret, A. et al. Evaluation of quinacrine treatment for prion diseases. J. Virol. 77, 8462-8469 (2003).
114. Race, R., Oldstone, M. & Chesebro, B. Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J. Virol. 74, 828-833 (2000).
115. Fischer, M. et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 15, 1255-1264 (1996).
116. Beringue, V., Adjou, K. T., Lamoury, F., Maignien, T., Deslys, J. P., Race, R. & Dormont, D. Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent. J. Virol. 74, 5432-5440 (2000).
117. Korth, C., May, B. C., Cohen, F. E. & Prusiner, S. B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl Acad. Sci. USA 98, 9836-9841 (2001).
118. Bate, C., Salmona, M., Diomede, L. & Williams, A. Squalestatin cures prion-infected neurones and protects against prion neurotoxicity. J. Biol. Chem. (in the press).
119. Diringer, H. & Ehlers, B. Chemoprophylaxis of scrapie in mice. J. Gen. Virol. 72, 457-460 (1991).
120. Caughey, B. & Raymond, G. J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67, 643-650 (1993).
121. Gabizon, R., Meiner, Z., Halimi, M. & Bensasson, S. A. Heparin-like molecules bind differentially to prion proteins and change their intracellular metabolic-fate. J. Cell. Physiol. 157, 319-325 (1993).
122. Sc dependent cell-free formation of protease-resistant prion protein. EMBO J. 20, 377-386 (2001).
123. Ben-Zaken, O. et al. Cellular heparan sulfate participates in the metabolism of prions. J. Biol. Chem. 278, 40041-40049 (2003).
124. Deleault, N. R., Lucassen, R. W. & Supattapone, S. RNA molecules stimulate prion protein conversion. Nature 425, 717-720 (2003).
125. Caughey, B. & Kocisko, D. A. Prion diseases: a nucleic-acid accomplice? Nature 425, 673-674 (2003).
126. Caughey, B. & Race, R. E. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J. Neurochem. 59, 768-771 (1992).
127. Ingrosso, L., Ladogana A. & Pocchiari, M. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol. 69 506-508 (1995).
128. Caughey, B., Brown, K., Raymond, G. J., Katzenstien, G. E. & Thresher, W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and Congo red. J. Virol. 68, 2135-2141 (1994).
129. Caspi, S. et al. The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem. 273, 3484-3489 (1998).
130. Demaimay, R. et al. Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J. Neurochem. 71, 2534-2541 (1998).
131. Demaimay, R., Chesebro, B. & Caughey, B. Inhibition of formation of protease-resistant prior protein by trypan blue, sirius red and other Congo red analogs. Arch. Virol. [Suppl] 16, 277-283 (2000).
132. Poli, G. et al. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives. Arzneimittelforschung. 53, 875-888 (2003).
133. Gilch, S. et al. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J. 20, 3957-3966 (2001).
134. Caughey, B., et al. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol. 77, 5499-5502 (2003).
135. Priola, S. A., Raines, A. & Caughey, W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J. Infect. Dis. 188, 699-705 (2003).
136. Pocchiari, M., Schmittinger, S. & Masullo, C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J. Gen. Virol. 68, 219-223 (1987).
137. Dormont, D. Approaches to prophylaxis and therapy. Br. Med. Bull. 66, 281-292 (2003).
138. Mange, A. et al. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J. Virol. 74, 3135-3140 (2000).
139. Marella, M., Lehmann, S., Grassi, J. & Chabry, J. Filipin prevents pathological prior protein accumulation by reducing endocytosis and inducing cellular PrP release. J. Biol. Chem. 277, 25457-25464 (2002).
140. Adjou, K. T. et al. MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters. J. Comp. Pathol. 122, 3-8 (2000).
141. Doh-ura, K., Iwaki, T. & Caughey, B. Lysosomotropic agents and cysteine protease inhibitors inhibit accumulation of scrapie-associated prion protein. J. Virol. 74, 4894-4897 (2000).
142. Sigurdsson, E. M. et al. Copper chelation delays the onset of prion disease. J. Biol. Chem. 278, 46199-46202 (2003).
143. Scott, M. R., Kohler, R., Foster, D. & Prusiner, S. B. Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci. 1, 986-997 (1992).
144. Priola, S. A., Caughey, B., Race, R. E. & Chesebro, B. Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J. Virol. 68, 4873-4878 (1994).
145. Horiuchi, M., Priola, S. A., Chabry, J. & Caughey, B. Interactions between heterologous forms of prior protein: Binding, inhibition of conversion, and species barriers. Proc. Natl Acad. Sci. USA 97, 5836-5841 (2000).
146. Goldmann, W., Hunter, N., Smith, G., Foster, J. & Hope, J. PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. J. Gen. Virol. 75, 989-995 (1994).
147. Palmer, M. S., Dryden, A. J., Hughes, J. T. & Collinge, J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340-342 (1991).
148. Prusiner, S. B. et al. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63, 673-686 (1990).
149. Chabry, J., Caughey, B. & Chesebro, B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. 273, 13203-13207 (1998).
150. Chabry, J. et al. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J. Virol. 73, 6245-6250 (1999).
151. Brown, P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 58, 1720-1725 (2002).
152. Doh-ura, K. et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. 78, 4999-5006 (2004).
153. Kobayashi, Y., Hirata, K., Tanaka, H. & Yamada, T. [Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft - an EEG evaluation]. Rinsho Shinkeigaku 43, 403-408 (2003).
154. Nakajima, M. et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn Disord. 17, 158-163 (2004).
155. Otto, M. et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 62, 714-718 (2004).
156. Taylor, D. M. Inactivation of transmissible degenerative encephalopathy agents: a review. Vet. J. 159, 10-17 (2000).
157. Kocisko, D. A., Morrey, J. D., Race, R., Chen, J. & Caughey, B. Evaluation of new cell-culture inhibitors of PrP-res against scrapie infection in mice. J. Gen. Virol. 85, 2479-2484 (2004).
158. Daude, N., Marella, M. & Chabry, J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J. Cell Sci. 116, 2775-2779 (2003).
159. Prusiner, S. B. Shattuck lecture - neurodegenerative diseases and prions. N. Engl. J. Med. 344, 1516-1526 (2001).
160. Caughey, B. & Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
161. Kimberlin, R. H. & Walker, C. A. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch. Virol. 78, 9-18 (1983).
162. Lasmezas, C. I. et al. Transmission of the ESE agent to mice in the absence of detectable abnormal prion protein. Science 17, 402-405 (1997).